Anesthetic propofol reduces endotoxic inflammation by inhibiting reactive oxygen species-regulated Akt/IKKβ/NF-κB signaling

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Hsing, Chung Hsi ^a,b   Lin, Ming Chung ^a,c   Choi, Pui Ching ^c   Huang, Wei Ching ^c   Kai, Jui In ^c   Tsai, Cheng Chieh ^c,d   Cheng, Yi Lin ^c   Hsieh, Chia Yuan ^c   Wang, Chi Yun ^c   Chang, Yu Ping ^c   Chen, Yu Hong ^c   Chen, Chia Ling ^c   Lin, Chiou Feng ^c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; NITRIC OXIDE; PROPOFOL; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; ENDOTOXIN; I KAPPA B KINASE; INTRAVENOUS ANESTHETIC AGENT; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL DEATH; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY;

BACTERIA (MICROORGANISMS); MURINAE; MUS;

ANESTHETICS, INTRAVENOUS; ANIMALS; CELL DEATH; CYTOKINES; ENDOTOXINS; ENZYME ACTIVATION; I-KAPPA B KINASE; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROPOFOL; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 79952412498     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017598     Document Type: Article

References (38)

1. Mackenzie N, Grant IS, (1987) Propofol for intravenous sedation. Anaesthesia 42: 3-6.
2. Marik PE, (2005) Propofol: an immunomodulating agent. Pharmacotherapy 25: 28S-33S.
3. Taniguchi T, Kanakura H, Takemoto Y, Kidani Y, Yamamoto K, (2003) Effects of ketamine and propofol on the ratio of interleukin-6 to interleukin-10 during endotoxemia in rats. Tohoku J Exp Med 200: 85-92.
4. Takemoto Y, (2005) Dose effects of propofol on hemodynamic and cytokine responses to endotoxemia in rats. J Anesth 19: 40-44.
5. Hsu BG, Yang FL, Lee RP, Peng TC, Chen HI, (2005) Effects of post-treatment with low-dose propofol on inflammatory responses to lipopolysaccharide-induced shock in conscious rats. Clin Exp Pharmacol Physiol 32: 24-29.
6. Hsing CH, Chou W, Wang JJ, Chen HW, Yeh CH, (2010) Propofol increases bone morphogenetic protein-7 and decreases oxidative stress in sepsis-induced acute kidney injury. Nephrol Dial Transplant In press.
7. Chen HI, Hsieh NK, Kao SJ, Su CF, (2008) Protective effects of propofol on acute lung injury induced by oleic acid in conscious rats. Crit Care Med 36: 1214-1221.
8. Chen RM, Chen TG, Chen TL, Lin LL, Chang CC, et al. (2005) Anti-inflammatory and antioxidative effects of propofol on lipopolysaccharide-activated macrophages. Ann N Y Acad Sci 1042: 262-271.
9. Takaono M, Yogosawa T, Okawa-Takatsuji M, Aotsuka S, (2002) Effects of intravenous anesthetics on interleukin (IL)-6 and IL-10 production by lipopolysaccharide-stimulated mononuclear cells from healthy volunteers. Acta Anaesthesiol Scand 46: 176-179.
10. Ma L, Wu X, Chen W, Fujino Y, (2010) Propofol has anti-inflammatory effects on alveolar type II epithelial cells. Acta Anaesthesiol Scand 54: 362-369.
11. Inada T, Kubo K, Kambara T, Shingu K, (2009) Propofol inhibits cyclo-oxygenase activity in human monocytic THP-1 cells. Can J Anaesth 56: 222-229.
12. Song XM, Wang YL, Li JG, Wang CY, Zhou Q, et al. (2009) Effects of propofol on pro-inflammatory cytokines and nuclear factor kappaB during polymicrobial sepsis in rats. Mol Biol Rep 36: 2345-2351.
13. Wu GJ, Chen TL, Chang CC, Chen RM, (2009) Propofol suppresses tumor necrosis factor-alpha biosynthesis in lipopolysaccharide-stimulated macrophages possibly through downregulation of nuclear factor-kappa B-mediated toll-like receptor 4 gene expression. Chem Biol Interact 180: 465-471.
14. Chiu WT, Lin YL, Chou CW, Chen RM, (2009) Propofol inhibits lipoteichoic acid-induced iNOS gene expression in macrophages possibly through downregulation of toll-like receptor 2-mediated activation of Raf-MEK1/2-ERK1/2-IKK-NFkappaB. Chem Biol Interact 181: 430-439.
15. Brasil LJ, San-Miguel B, Kretzmann NA, Amaral JL, Zettler CG, et al. (2006) Halothane induces oxidative stress and NF-kappaB activation in rat liver: protective effect of propofol. Toxicology 227: 53-61.
16. Jawan B, Kao YH, Goto S, Pan MC, Lin YC, et al. (2008) Propofol pretreatment attenuates LPS-induced granulocyte-macrophage colony-stimulating factor production in cultured hepatocytes by suppressing MAPK/ERK activity and NF-kappaB translocation. Toxicol Appl Pharmacol 229: 362-373.
17. Riedemann NC, Guo RF, Ward PA, (2003) Novel strategies for the treatment of sepsis. Nat Med 9: 517-524.
18. Lawton JA, Ghosh P, (2003) Novel therapeutic strategies based on toll-like receptor signaling. Curr Opin Chem Biol 7: 446-451.
19. Lin CF, Chen CL, Chiang CW, Jan MS, Huang WC, et al. (2007) GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J Cell Sci 120: 2935-2943.
20. Huang WC, Lin YS, Wang CY, Tsai CC, Tseng HC, et al. (2009) Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology 128: e275-286.
21. Yang F, Tang E, Guan K, Wang CY, (2003) IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 170: 5630-5635.
22. Hacker H, Karin M, (2006) Regulation and function of IKK and IKK-related kinases. Sci STKE 2006: re13.
23. Ojaniemi M, Glumoff V, Harju K, Liljeroos M, Vuori K, et al. (2003) Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol 33: 597-605.
24. Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E, (2004) Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 172: 2522-2529.
25. Jang SI, Kim HJ, Kim YJ, Jeong SI, You YO, (2006) Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 542: 1-7.
26. Kim JH, Na HJ, Kim CK, Kim JY, Ha KS, et al. (2008) The non-provitamin A carotenoid, lutein, inhibits NF-kappaB-dependent gene expression through redox-based regulation of the phosphatidylinositol 3-kinase/PTEN/Akt and NF-kappaB-inducing kinase pathways: role of H(2)O(2) in NF-kappaB activation. Free Radic Biol Med 45: 885-896.
27. Koay MA, Christman JW, Segal BH, Venkatakrishnan A, Blackwell TR, et al. (2001) Impaired pulmonary NF-kappaB activation in response to lipopolysaccharide in NADPH oxidase-deficient mice. Infect Immun 69: 5991-5996.
28. Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, et al. (2001) Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem 276: 30188-30198.
29. Vasile B, Rasulo F, Candiani A, Latronico N, (2003) The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 29: 1417-1425.
30. Fudickar A, Bein B, (2009) Propofol infusion syndrome: update of clinical manifestation and pathophysiology. Minerva Anestesiol 75: 339-344.
31. Kwak SH, Choi JI, Park JT, (2004) Effects of propofol on endotoxin-induced acute lung injury in rabbit. J Korean Med Sci 19: 55-61.
32. Tsao CM, Ho ST, Liaw WJ, Chen A, Wu CC, (2008) Combined effects of propofol and dexamethasone on rats with endotoxemia. Crit Care Med 36: 887-894.
33. Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P, (2008) Experimental models of sepsis and their clinical relevance. Shock 30 (Suppl 1): 53-59.
34. Nomellini V, Gomez CR, Gamelli RL, Kovacs EJ, (2009) Aging and animal models of systemic insult: trauma, burn, and sepsis. Shock 31: 11-20.
35. Haddad JJ, (2002) Oxygen-sensitive pro-inflammatory cytokines, apoptosis signaling and redox-responsive transcription factors in development and pathophysiology. Cytokines Cell Mol Ther 7: 1-14.
36. Macdonald J, Galley HF, Webster NR, (2003) Oxidative stress and gene expression in sepsis. Br J Anaesth 90: 221-232.
37. Rinaldi S, Landucci F, De Gaudio AR, (2009) Antioxidant therapy in critically septic patients. Curr Drug Targets 10: 872-880.
38. Victor VM, Espulgues JV, Hernandez-Mijares A, Rocha M, (2009) Oxidative stress and mitochondrial dysfunction in sepsis: a potential therapy with mitochondria-targeted antioxidants. Infect Disord Drug Targets 9: 376-389.